Capecitabine in the treatment of colorectal cancer

Future Oncology

Volumn 1, Issue 2, 2005, Pages 183-190

  O'Neill, V J ^a   Cassidy, J ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

capecitabine; colorectal cancer

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; PRODRUG;

COLORECTAL TUMOR; FORECASTING; HUMAN; PATHOLOGY; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FORECASTING; HUMANS; PRODRUGS;

EID: 33646450317     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.2.183     Document Type: Article

References (26)

1. Miwa M, Ura M, Nishida M et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34(8), 1274-1281 (1998)
2. Moghaddam A, Zhang HT, Fan TP et al.: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl Acad. Sci. USA 92(4), 998-1002 (1995)
3. Schuller J, Cassidy J, Dumont E et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45(4), 291-297 (2000)
4. Reigner B, Blesch K, Weidekamm: Clinical pharmacokinetics of capecitabine. E. Clin. Pharmacokinet. 40(2), 85-104 (2001)
5. Judson IR, Beale PJ, Trigo JM et al.: A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest. New Drugs 17(1), 49-56 (1999)
6. Mackean M, Planting A, Twelves C et al.: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 16(9), 2977-2985 (1998)
7. Budman DR, Meropol NJ, Reigner B et al.: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol. 16(5), 1795-1802 (1998)
8. Cassidy J, Dirix L, Bissett D et al.: A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin. Cancer Res. 4(11), 2755-2761 (1998)
9. Van Cutsem E, Findlay M, Osterwalder B et al.: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study. J. Clin. Oncol. 18(6), 1337-1345 (2000)
10. Hoff PM, Ansari R, Batist G et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19(8), 2282-2292 (2001)
11. Van Cutsem E, Twelves C, Cassidy J et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. 19(21), 4097-4106 (2001)
12. Van Cutsem E, Hoff PM, Harper P et al.: Oral capecitabine vs intravenous 5- fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br. J. Cancer 90(6), 1190-1197 (2004)
13. Cassidy J, Twelves C, Van Cutsem E et al.: First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5 florouracil/leucovorin. Ann. Oncol. 13(4), 566-575 (2002)
14. Cassidy J, Scheithauer W, J McKendrick, H et al.: on behalf of the X-ACT study investigators capecitabine (X) vs. bolus 5- FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a Phase III trial. ASCO [Abstract] 3509 (2004)
15. Scheithauer W, McKendrick J, Begbie S et al.: X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5- fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann Oncol. 12, 1735-1743 (2003)
16. Goldberg RM, Sargent DJ, Morton RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1), 23-30 (2004)
17. Cassidy J, Tabernero J, Twelves C et al.: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 22(11), 2084-2091 (2004)
18. de Gramont, Figer A, Seymour M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000)
19. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004)
20. Patt YZ, Liebmann J, Diamandidis D et al.: Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): final safety findings from a Phase II trial. Proc. Am. Soc. Clin. Oncol. [Abstract 3602] (2004)
21. Kerr DJ, Ten Bokkel Huinink W,Ferry DR, et al.: A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC) ASCO (2002)
22. Delord JP, Pierga JY, Dieras V et al.: Dose escalation and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT- 11) in gastro-intestinal tumors: preliminary results. ASCO (2002)
23. Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J. Clin. Oncol. 22(11), 2214-2232 (2004)
24. Dunst J, Reese T, Sutter T et al.: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J. Clin. Oncol. 20(19), 3983-3991 (2002)
25. Ngan SY, Michael M, Mackay J et al.: A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br. J. Cancer 91(6), 1019-1024 (2004)
26. Twelves C, Xeloda Colorectal Cancer Group: Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur. J. Cancer 38 (2), 15-20 (2002)